Paul L. Chazot

Paul L. Chazot

School of Biological & Biomedical Sciences, Durham University, South Road, Durham, DH1 3LE, United Kingdom

Biography
Dr Chazot has developed two new clinical development programmes over the last 20 years, one for chronic pain (Votucalis), and one for Alzheimer’s Disease (PBM-T 1068nm), the former at the pipeline stage for the company Akari Therapeutics UK, and the latter reaching the FDA Phase 2b clinical stage in the US. He is also the Durham lead for the Durham University spin-out company Nevrargenics, who has developed exciting new rational drug leads (RAR-M) for disease-modifying in a range of neurodegenerative diseases.